KAMAU THERAPEUTICS
Live / Applied — Fourth extension granted (statement of use) (as of 10 Sept 2026)
What this means for you
Not registered yet, but its 11 Aug 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98128117
- Mark type
- Stylized text
- Filed
- 11 Aug 2023
- Published for opposition
- 13 Aug 2024
- Attorney of record
- Connie Ellerbach
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations in the nature of genetically modified cells for use in the treatment of genetic diseases and disorders; pharmaceutical preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for gene therapy, gene editing, genome editing, and targeted gene replacement and insertion; cell therapy products in the nature of genetically modified cells for the treatment of genetic diseases and disorders; gene therapy products in the nature of genetically engineered human genes for the treatment of genetic diseases and disorders; pharmaceutical preparations for non-genotoxic conditioning to enable engraftment; pharmaceutical preparations containing templates of DNA sequences to restore and normalize the function in a disease-causing gene; gene edited and corrected human cells for medical use
- Class 042 — Scientific and technological services: Pharmaceutical research and development services; Research in the fields of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; research and development of therapeutics pharmaceuticals using gene editing; providing medical and scientific research information in the field of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; research in the field of clustered regularly interspaced short palindromic repeats (CRISPR) and homology directed repair (HDR) technologies
Owner
- Kamau Therapeutics, Inc., South San Francisco, CA, US
- Kamau Therapeutics, Inc., South San Francisco, CA, US
Prosecution history
- 11 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Sept 2026 — SOU EXTENSION 4 GRANTED
- 10 Sept 2026 — SOU EXTENSION 4 FILED
- 10 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 11 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Mar 2026 — SOU EXTENSION 3 GRANTED
- 10 Mar 2026 — SOU EXTENSION 3 FILED
- 10 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 01 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2025 — SOU EXTENSION 2 GRANTED
- 01 Oct 2025 — SOU EXTENSION 2 FILED
- 01 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 28 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Mar 2025 — SOU EXTENSION 1 GRANTED
- 27 Mar 2025 — SOU EXTENSION 1 FILED